Bildkälla: Stockfoto

Xbrane Biopharma Q2: Xlucane™ Launch Anticipated to Q1’23 - Redeye

Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane™, anticipated in Q1 2023.

Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane™, anticipated in Q1 2023.
Börsvärldens nyhetsbrev
ANNONSER